Murchinson Criticizes the Nano Dimension Board of Directors’ Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics

▤ Summary

This title points to an investor or shareholder dispute over Nano Dimension’s board decision to pursue a transaction with Infinite Epigenetics. The focus is on governance, deal quality, and strategic direction rather than a product, funding round, or operating update. The event may matter to software and technology investors, but it is not a direct software industry business milestone. Because the article text is empty, no further operational detail is available.

▦ Linked Companies

Nano Dimension

$50M to $100M